Cancer

Progen Pharmaceuticals Outlines Preliminary Phase 3 Clinical Trial Design - Patient Enrollment Planned for Second Half of 2007-

Published in Cancer Weekly, July 24th, 2007

Progen Pharmaceuticals Limited (NASDAQ:PGLA) announced key features of its Phase 3 clinical trial design for its anti-cancer treatment for liver cancer, PI-88. The design will allow for a potentially faster and more cost effective trial with a higher likelihood of success than previously reported.

Progen has used key outcomes from its Phase 2 trial and combined input from its Phase 3 Clinical Advisory Board, specialist advisers, and the FDA to design a Phase 3 trial with optimized probability of success. One key design feature of the Phase 3 trial will be the use of disease-free survival (DFS) as a primary endpoint, which reduces the overall cost and timelines...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-07-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry